Jump to main content
US EPA
United States Environmental Protection Agency
Search
Search
Main menu
Environmental Topics
Laws & Regulations
About EPA
Health & Environmental Research Online (HERO)
Contact Us
Print
Feedback
Export to File
Search:
This record has one attached file:
Add More Files
Attach File(s):
Display Name for File*:
Save
Citation
Tags
HERO ID
7438652
Reference Type
Journal Article
Title
Chemotherapy and Prostate Cancer
Author(s)
Tsang, ML; ,
Year
2021
Publisher
Springer International Publishing
Location
Cham
Book Title
Chemotherapy and Immunotherapy in Urologic Oncology
Page Numbers
105-118
DOI
10.1007/978-3-030-52021-2_9
URL
http://link.springer.com/10.1007/978-3-030-52021-2_9
Exit
Abstract
Chemotherapy treatment options for prostate cancer (PC) are very limited and it may not always be indicated depending on the disease state. The three FDA-approved chemotherapies for PC are docetaxel, cabazitaxel, and mitoxantrone in combination with prednisone. The most common cytotoxic chemotherapy is taxane derivatives. Docetaxel is used as first-line chemotherapy with metastatic hormone-sensitive prostate cancer (mHSPC) and metastatic castration-resistant prostate cancer (mCRPC) patients. Cabazitaxel is used as second-line chemotherapy when patients do not tolerate or progressed during or after docetaxel with mCRPC patients. The taxane derivatives have shown to improve overall survival in men with mCRPC. Other chemotherapies like carboplatin, etoposide, or cisplatin may be considered when mCRPC patients with visceral metastases involving neuroendocrine or small cell features upon biopsy. Side effects that are commonly associated with these chemotherapies are fatigue, nausea, vomiting, taste change, mouth sores, nail changes, liver toxicity, alopecia, renal toxicity, neutropenia, anemia, thrombocytopenia, fluid retention/edema. Closely monitor laboratory results, and side effects prior to each administration is crucial to prevent severe toxicities. Due to the limitation of chemotherapy option for PC patients, ongoing clinical trials are needed to investigate and develop more treatment options for patients with PC.
Home
Learn about HERO
Using HERO
Search HERO
Projects in HERO
Risk Assessment
Transparency & Integrity